Plasma Fractionation Market Strategic Outlook, Growth Insights, and Forecast Opportunities 2032

The plasma fractionation market focuses on separating human plasma into its essential components—such as immunoglobulins, albumin, coagulation factors, and other plasma-derived proteins—used to treat a wide range of conditions, including immune deficiencies, hemophilia, liver diseases, and neurological disorders. Plasma fractionation ensures the safe and efficient utilization of donated plasma for life-saving therapies. Market growth is driven by the rising prevalence of chronic and rare diseases, growing demand for immunoglobulin therapies, and advancements in plasma collection and purification technologies. Increasing awareness about plasma-derived treatments and expanding healthcare access in emerging markets are also contributing to market expansion.

The global plasma fractionation market size was valued at USD 37.31 billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a strong CAGR of 8.75% during the forecast period. This growth is primarily driven by the increasing demand for plasma-derived therapies used in treating rare and chronic diseases such as hemophilia, immunodeficiency disorders, and liver diseases.

North America dominated the plasma fractionation market in 2024 with a market share of 56.18%, owing to its well-established healthcare infrastructure, advanced plasma collection systems, and strong presence of key industry players.

Market Drivers & Restraints

Drivers

• Increasing prevalence of immune and neurological disorders driving the demand for immunoglobulin therapies.

• Technological advancements in plasma separation and purification processes improving product efficiency.

• Growing adoption of plasma-derived therapies for rare and chronic diseases.

• Expansion of plasma collection centers and enhanced healthcare infrastructure worldwide.

Restraints

• High cost of plasma-derived products and limited reimbursement in developing countries.

• Stringent regulatory frameworks and approval timelines affecting new product launches.

• Competition from recombinant and alternative biologic therapies.

• Shortages in plasma supply due to collection and logistics challenges.

Top Companies in the Market

• CSL Behring (CSL) (U.S.)

• Grifols, S.A (Spain)

• Takeda Pharmaceutical Company Limited (Japan)

• Kedrion S.p.A (Italy)

• Octapharma (Switzerland)

• ADMA Biologics, Inc. (U.S.)

• Sartorius AG (Germany)

• LFB (France)

Market Segments

By Product

• Immunoglobulin: Dominates the market due to rising demand in immunology and neurology applications.

• Albumin: Widely used for liver disorders, burns, and shock, contributing a substantial share to revenue.

• Coagulation Factors: Increasing use in treating hemophilia and bleeding disorders.

• Protease Inhibitors and Others: Expected to show steady growth in specialized therapeutic areas.

By Application

• Immunology & Neurology: Accounts for the largest market share due to higher prevalence of autoimmune diseases.

• Hematology: Significant growth driven by the demand for coagulation factors and plasma-based treatments.

• Critical Care: Increasing adoption of albumin and coagulation products in intensive care units.

• Pulmonology and Others: Growing use of immunoglobulins in respiratory and infectious disease management.

By End-User

• Hospitals & Clinics: Dominant segment accounting for over 80% of revenue share in 2024.

• Clinical Research Laboratories: Expected to record the fastest growth owing to increased clinical studies.

• Others: Includes academic institutions and specialty centers contributing to research activities.

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614 

Market Regional Insights

North America

North America held the largest market share in 2024, valued at USD 20.96 billion. The region’s dominance is attributed to a strong plasma collection network, favorable reimbursement policies, and the presence of leading players such as CSL Behring and Grifols. The U.S. continues to be the largest contributor due to high healthcare expenditure and growing awareness of plasma-derived therapies.

Europe

Europe accounted for a significant portion of global revenue, driven by increased investment in plasma fractionation facilities and greater adoption of immunoglobulin therapies. Germany and France lead the European market with strong healthcare infrastructure and government support for plasma-based treatments.

Future Market Scope

The plasma fractionation market is expected to reach USD 72.45 billion by 2032. Growth will be driven by continued innovation in purification technologies, increased plasma donations, and broader therapeutic indications for plasma-derived products. Emerging economies are likely to see significant development as governments and private organizations expand collection and manufacturing capacities. Automation, digital monitoring, and next-generation purification systems will further improve plasma yield and quality. In addition, the shift toward personalized therapies and expansion of recombinant alternatives may influence future market dynamics, encouraging companies to diversify their product portfolios.

Key Industry Development

July 2024: Kedrion S.p.A. announced a long-term agreement with Biotest AG for the full commercialization and distribution of the immunoglobulin therapy Yimmugo in the U.S. market. This collaboration aims to enhance Kedrion’s presence in the U.S. and expand patient access to innovative immunoglobulin treatments.

Conclusion

The global plasma fractionation market is evolving rapidly, supported by the growing demand for plasma-derived therapies and continuous advancements in biotechnology. Strong collaborations, increased production capacities, and new treatment approvals will further strengthen the industry outlook. As healthcare systems worldwide emphasize patient safety and treatment efficiency, the plasma fractionation market is poised to play a critical role in the future of therapeutic medicine.

About Us:Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com